Global Autoimmune Hepatitis Market, By Type (Type 1, Type 2), Treatment (Medications, Liver Transplant, Others), Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030
Market Overview
In recent years, the autoimmune hepatitis market is anticipated to grow rapidly during the forecast period. According to the 2019 study "Burden of Liver Diseases in the World," liver illness causes roughly 2 million fatalities worldwide, with 1 million deaths due to cirrhosis complications and 1 million deaths due to viral hepatitis and hepatocellular cancer. Cirrhosis is the 11th most prevalent cause of mortality globally, while liver cancer is the 16th most common cause of death. They are responsible for 3.5 percent of all deaths worldwide.
According to Pharmanucleus, the autoimmune hepatitis market was valued at USD 156.76 million in 2021 and is predicted to reach USD 210.61 million by 2030, showing a CAGR of 3.70% from 2023 to 2030. The Pharmanucleus team curated the market study, which contains extensive expert analysis, patient epidemiology, pipeline analysis, price analysis, and regulatory framework.
Market Definition
Autoimmune hepatitis is an uncommon but fatal liver disease. When the body mistakes healthy tissue and cells for infectious tissue and cells, antibodies are created to target the healthy liver cells. Autoimmune hepatitis can develop quickly or gradually. The condition's aetiology is unknown, however it may be related to other systemic disorders or medication exposure in some situations.
Autoimmune Hepatitis Market Dynamics
Drivers
- Increased incidence of autoimmune hepatitis
The rising prevalence of autoimmune hepatitis is a major contributor to the market's rapid expansion. Complications of such illnesses include swollen veins in the oesophagus, fluid accumulation in the abdomen, liver failure, and liver cancer.
- Increasing healthcare infrastructure investment
Growing healthcare spending, which aids in infrastructure improvement, is another important aspect driving the autoimmune hepatitis market's growth rate.
The greater governmental and private-sector efforts to promote awareness of the would boost the autoimmune hepatitis market. Furthermore, people's changing lifestyles and high disposable income will drive the autoimmune hepatitis market upward. Furthermore, the expanding older population and an increase in medical tourism will accelerate the market's development pace.
Opportunities
- Increase in the number of R&D activities
Moreover, when R&D activity increases, so does the market. This will create new prospects for the autoimmune hepatitis industry to expand. Additionally, higher medication approvals and launches will drive market growth.
Furthermore, rising investments in the development of innovative technologies, as well as an increase in the number of emerging markets, will create further chances for the autoimmune hepatitis market to expand throughout the projected period..
Restraints/Challenges
On the other hand, the high cost of treatment will hamper the growth rate of the market. Lack of healthcare infrastructure in developing economies and low awareness of autoimmune hepatitis will pose major challenges to the market growth rate. Additionally, shortage of skilled professionals and missed diagnoses will further limit and hamper the growth rate of the market over the forecast period 2023-2030.
This report on the Autoimmune Hepatitis Market discusses recent new developments, trade regulations, import-export analysis, production analysis, value chain optimisation, share market analysis, the impact of national and localised market players, analyses opportunities in terms of emerging revenue pockets, market changes regulations, strategic analysis of market growth, market size, category market growth, niches and dominance of applications, product approvals, and p Contact Pharmanucleus for an Analyst Brief for more information on the Autoimmune Hepatitis industry; our experts will assist you in making an informed market choice to achieve market growth.
Patient Epidemiology Analysis
Autoimmune hepatitis is an uncommon condition that affects four times as many women as males. Type 1 diabetes is the most common and affects most individuals. Type 2 diabetes is more frequent in young individuals and progresses faster. Every year, 1 to 2 new cases per 100,000 people are expected, for a total of around 24 cases per 100,000 people.
Furthermore, the Autoimmune Hepatitis Market offers in-depth market data for patient analysis, prognosis, and therapy. Prevalence, incidence, mortality, and adherence rates are among the statistical aspects evaluated in the study. Analyses of the direct or indirect influence of epidemiology on market growth are performed in order to develop a more robust cohort multivariate statistical model to forecast market growth during the boom era.
Post COVID Impact
Since its emergence in December 2019, the COVID-19 virus has indeed had a profound impact on healthcare systems worldwide, which has affected various medical conditions, including autoimmune hepatitis. The declaration of the virus as a public health emergency by the World Health Organization (WHO) prompted healthcare systems to prioritize COVID-19-related treatments and control measures. As a result, specialist healthcare services for other conditions, including autoimmune hepatitis, have faced delays and disruptions.
The financial crisis caused by the pandemic has further compounded the challenges in healthcare systems, leading to resource constraints and reduced access to medical services. Patients with autoimmune hepatitis have faced difficulties in seeing their healthcare providers for various reasons. Some individuals have struggled to access doctors due to overwhelmed healthcare facilities or limited availability of appointments. Fear of contracting the virus has also deterred patients from seeking in-person consultations. Moreover, pandemic-related restrictions, such as lockdowns and travel limitations, have hindered the continuity of essential therapies and procedures for autoimmune hepatitis patients.
These circumstances have the potential to negatively impact the autoimmune hepatitis market in recent months. Reduced access to care, delayed diagnoses, and interruptions in treatment may result in suboptimal disease management, increased disease progression, and worsened patient outcomes. Additionally, the economic consequences of the pandemic may limit patients' ability to afford necessary medications and therapies, affecting market demand.
However, as the global healthcare system adapts and recovers from the pandemic, efforts are being made to address these challenges. Telemedicine and remote healthcare services have gained prominence, allowing patients to connect with their healthcare providers virtually. Gradual easing of pandemic restrictions and resumption of regular healthcare services are expected to alleviate some of the barriers faced by autoimmune hepatitis patients, helping to stabilize the market over time.
Global Autoimmune Hepatitis Market Scope
The market for autoimmune hepatitis is classified by type, therapy, diagnosis, method of administration, end-users, and distribution channel. The growth in these segments will assist you in analysing the growth sectors in industries and providing users with a beneficial market overview and industry insights to assist them in making strategic decisions for finding key market applications.
By Type
- Type 1
- Type 2
By Treatment
- Medications
- Corticosteroids
- Immune system suppressors
- Liver Transplant
- Others
By Diagnosis
- Liver Biopsy
- Blood Tests
- Imaging Tests
- Ultrasound
- MRI
- CT scan
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
By End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Autoimmune Hepatitis Market Regional Analysis/Insights
The Autoimmune Hepatitis Market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end users and distribution channel as listed above.
The countries covered in the Autoimmune Hepatitis market report are USA, Canada, and Mexico North America, Germany, France, UK, Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, the rest of Europe in Europe, China, Japan and India. , South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America is dominating the autoimmune hepatitis market due to growing presence of major key players and growing number of research and development activities will further propel the market growth rate in this region. Additionally, increasing number of FDA approved drugs will further propel the market growth rate in this region.
The Asia-Pacific region is expected to witness growth over the forecast period owing to the increasing number of generic manufacturers and increasing government initiatives in this region. Also, the development of healthcare infrastructure will further boost the market growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in market regulations that impact current and future market trends. Data points such as upstream and downstream value chain analysis, technical trends and bearer five forces analysis, case studies are some of the indicators used to forecast the market scenario for each country. In addition, the presence and availability of global brands and the challenges they face due to significant or rare competition from local and national brands, the impact of domestic tariffs and trade routes are considered while providing a forecast analysis of national data.
Competitive Landscape and Autoimmune Hepatitis Market Share Analysis
The competitive landscape for the Autoimmune Hepatitis market gives information by competitor. Company overview, financials, revenue generated, market potential, R&D investment, new market initiatives, global presence, locations and manufacturing facilities, production capacities, company strengths and weaknesses, product launch, product breadth and breadth, and application dominance are all included. The data presented above is just for firms involved in the autoimmune hepatitis market.
Some of the major players operating in the autoimmune hepatitis market are:
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Bayer AG (Germany)
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (US)
- Cadila Pharmaceuticals (India)
- Eli Lilly and Company (US)
- LEO Pharma A/S (Denmark)
- Cipla Inc. (US)
- Aurobindo Pharma (India)
- Lupin (India)
Sumitomo Corporation (Japan)